PTC Therapeutics won a competitive auction to acquire Sangamo’s Fabry gene therapy program ST-920 (isaralgagene civaparvovec). Under the terms reported, Sangamo will receive $111 million upfront and another $100 million tied to regulatory milestones. The deal emerged from Sangamo’s bankruptcy asset sale process, with PTC outbidding Astellas and TerSera Therapeutics. ST-920 is designed to deliver a functional copy of alpha-galactosidase A via one-time AAV gene therapy to address underlying enzyme deficiency in Fabry disease. During Sangamo’s Phase I/II STAAR study, participants on enzyme replacement therapy stopped treatment following dosing, supporting the concept of a durable shift in disease biology. PTC positioned the acquisition as a route to accelerate revenue growth without a full internal build.